Walmart shares fell Friday after recording their largest one-day loss in more than a year yesterday following the release of a disappointing outlook from the retail giant. Monitor these important ...
Globant was the worst-performing stock of the week, falling 32.41%. This 3-star, narrow-moat company has increased 2.56% over the last three months and increased 5.45% over the past 12 months. The ...
The Dow Jones Industrial Average was under pressure in late-afternoon trading, with the U.S. stock index on pace for potentially its biggest weekly loss since October. The Dow was tumbling 776 points ...
Here are some of the major companies whose stocks moved on the week’s news.
The U.S. stock market struggled Friday, with the Dow Jones Industrial Average seeing its biggest weekly drop since October as investors assessed a survey showing consumer sentiment soured. The Dow ...
14h
Investor's Business Daily on MSNStock Market Today: Dow Jones Plunges 750 Points; Nvidia Drops As Warren Buffett Report Looms With This Number On Watch (Live Coverage)The Dow Jones Industrial Average and the S&P 500 continued to suffer losses at midday in the stock market today as UnitedHealth fell amid a Department of Justice probe. The Dow was 0.8% lower — a ...
Stock futures were muted, and while U.S.-listed shares of Alibaba rose 4% premarket--the excitement from Asia--where Chinese stocks mounted a fierce rally after Alibaba reported strong results from ...
Marshfield’s Kevin Connolly has just finished his latest acoustic album, and he’ll be celebrating its release with a show ...
On shares to buy or sell on Tuesday, Sachin Gupta recommends Ashok Leyland Ltd, and Bajaj Finserv Ltd.
At last glance, DAL was down 0.4% at $65.15. The stock isn't too far removed from its Jan. 22, record high of $69.98, ...
12d
Investor's Business Daily on MSNDow Jones Futures Rise, New Trump Tariffs Loom; Tesla, Robinhood In FocusWith the stock market choppy, step back with weekly charts. Tesla is tumbling. Robinhood, Shopify are among big earnings on ...
Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results